Immunovaccine appoints new CEO; PaxVax inks herpes R&D pact;

> Immunovaccine ($IMV) has appointed Marc Mansour as CEO. Release

> NovaDigm Therapeutics has acquired the rights to three Candida vaccine antigens. Release

> PaxVax has signed an R&D collaboration with UC San Diego to develop a vaccine against herpes simplex virus infections. Release

> Australian company Admedus has raised 10.1 million AUD ($9.4 million) in a share purchase plan for therapeutic vaccines. More

> UNICEF has handed over 15 generators to Liberia's government to ensure proper and safe vaccine storage. Release

And Finally... 108 countries are better than the U.S. at vaccinating against measles. More

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

As a new coronavirus spreads, vaccine researchers have started work on candidates against the virus—and one could enter the clinic in a few months.

Merck's HPV vaccine Gardasil is delivering blockbuster sales as demand surges. But high demand has caused somewhat of a supply constraint.